Roche is making a bold move in the field of allogeneic cell therapy with its recent acquisition of Poseida Therapeutics, a San Diego-based biotech firm. This $1 billion upfront deal underscores Roche's commitment to expanding its portfolio in cell and gene therapies, particularly targeting blood
Gene therapy has made remarkable strides in recent years, with 20 approved indications in the United States and a record number of approvals in 2023. Investigational trials are rapidly increasing across various diseases, including hemophilia B, sickle cell disease, and Duchenne muscular dystrophy.
The article "Cardiovascular disease risk linked to early brain decline in men," published in the Journal of Neurology Neurosurgery & Psychiatry, examines the correlation between cardiovascular disease risk factors and brain health decline, with a specific focus on gender differences. The research
Recent advancements in the field of cancer immunotherapy have unveiled an exciting discovery that involves the molecule MR1 and vitamin B6. Researchers at Monash University Biomedicine Discovery Institute, in collaboration with the University of Melbourne, have found that MR1 can bind to a form of
Halitosis, commonly known as bad breath, is a condition that can significantly impact social interactions and quality of life, particularly in children. This distressing issue is often exacerbated by mouth breathing, a habit in many youngsters that compromises the natural antibacterial properties
Androgenetic alopecia (AGA), a condition affecting millions of men globally, is characterized by the progressive miniaturization of hair follicles, leading to significant hair loss. This condition is primarily caused by dihydrotestosterone (DHT), a testosterone derivative, as well as elevated
